Legal Opinion
In Re Lorazepam & Clorazepate Antitrust Litigation
District Court, District of Columbia
Decided January 24, 2008No. 1:99-cr-00276PublishedCited by 3 opinions
1Opinion of the Court
MEMORANDUM OPINION
THOMAS F. HOGAN, Chief Judge.
Pending before the Court are several motions. Blue Cross Blue Shield of Massachusetts (“BCBS-MA”), Blue Cross Blue Shield of Minnesota (“BCBS-MN”), Federated Mutual Insurance Company (“Federated”), and Health Care Service Corporation (“HCSC”) (collectively “Plaintiffs”) move the Court to treble damages [Docket Nos. 887 & 891]; Mylan Laboratories Inc. and Mylan Pharmaceuticals Inc., Cambrex Corporation, and Gyma Laboratories (“Defendants”) move for remittitur under Rule 59(e) [Docket No. 890]; and Defendants move the Court to dismiss Blue Cross…
2Cases cited25 opinions
- New Hampshire v. MaineSupreme Court of the United States · 2001
- State Farm Mutual Automobile Insurance v. CampbellSupreme Court of the United States · 2003
- Group Life & Health Insurance v. Royal Drug Co.Supreme Court of the United States · 1979
- International Fidelity Insurance v. WilsonMassachusetts Supreme Judicial Court · 1983
- Charles Carter v. District of Columbia, Maurice Turner, Chief, Metropolitan Police Department Charles Carter v. District of ColumbiaCourt of Appeals for the D.C. Circuit · 1986
20 more not listed; retrieve them via the Exa API.
3Cited by3 opinions
- Health Care Serv. Corp. v. Mylan Labs., Inc.District Court, District of Columbia · 2017
- Blue Cross and Blue Shield of Alabama v. CVS Pharmacy, Inc.District Court, D. Rhode Island · 2026
- In Re: lorazepam/cloraze v. Mylan LaboratoriesDistrict Court, District of Columbia · 2017